Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio

The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre

IDEAYA Biosciences enters license with Hengrui Pharma for a novel phase 1 DLL3 Topo-I-Payload ADC targeting SCLC and NET solid tumors

Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)

Akums signs Rs. 1,760 crore CDMO agreement with a leading global pharma company

The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities

Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL

According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million

Granules India FDA approval for ADHD treatment

Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study

Demonstrates vision gains with extended treatment intervals in retinal vein occlusion

Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy

Final decision from the European Commission is anticipated within the coming months

Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million

This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape

Laurus Labs invests in Laurus Bio

Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg

The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA